3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Acrocephalosyndactylia
6
Cholangiocarcinoma
4
Neoplasm Metastasis
3
Myeloproliferative Disorders
2
Endometrial Neoplasms
2
Carcinoma, Transitional Cell
2
Stomach Neoplasms
1
Solid Tumor
1
Recurrence
1
Oligodendroglioma
1
Neoplasms, Unknown Primary
1
Neoplasms
1
Multiple Myeloma
1
Lung Neoplasms
1
Glioma
1
Glioblastoma
1
Eosinophilia
1
Central Nervous System Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Advanced Malignancies
1
Interventions
Temozolomide
94
Radiotherapy
40
Bevacizumab
40
Lomustine
21
Radiation
18
Surgical Procedures, Operative
10
Carboplatin
9
pembrolizumab
8
Nivolumab
8
Carmustine
8
Irinotecan
7
IL13-PE38
6
Granulocyte-Macrophage Colony-Stimulating Factor
6
Flucytosine
6
Cyclophosphamide
6
ABT-414
6
vocimagene amiretrorepvec
5
depatuxizumab mafodotin
5
Valacyclovir
5
Drug Therapy
5
veledimex
4
sargramostim
4
enzastaurin
4
NVP-BKM120
4
Gemcitabine
4
Dianhydrogalactitol
4
Chlorotoxin
4
Aminolevulinic Acid
4
verubulin
3
selinexor
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Glioblastoma
×
pemigatinib
×
Clear all
NCT05267106
2025-12-30
FIGHT-209
Incyte Corporation
Phase 2
Terminated
83 enrolled
18 charts